PHARMARON：2023INTERIMREPORT.pdf

《PHARMARON：2023INTERIMREPORT.pdf》由会员分享，可在线阅读，更多相关《PHARMARON：2023INTERIMREPORT.pdf（99页珍藏版）》请在三个皮匠报告上搜索。

1、Pharmaron Beijing Co.,Ltd.*Pharmaron Beijing Co.,Ltd.*(a joint stock company incorporated in the Peoples Republic of China with limited liability)Stock Code:3759*For identification purposes only2023INTERIMREPORTAbout PharmaronPharmaron(Stock Code:300759.SZ/3759.HK)is a premier R&D service provider f

2、or the life sciences industry.Founded in 2004,Pharmaron has invested in its people and facilities and established a broad spectrum of research,development and manufacturing service capabilities throughout the entire drug discovery,preclinical and clinical development process across multiple therapeu

3、tic modalities,including small molecules,biologics and CGT products.With around 20,000 employees,and operations in China,U.S.,and U.K.,Pharmaron has an excellent track record in the delivery of R&D solutions to its partners in North America,Europe,Japan and China.PREMIER R&D SERVICE PROVIDER FOR THE

4、 LIFE SCIENCES INDUSTRYCONTENTSCorporate InformationFinancial HighlightsManagement Discussion and AnalysisSupplementary InformationInterim Condensed Consolidated Statement of Profit or LossInterim Condensed Consolidated Statement of Comprehensive IncomeInterim Condensed Consolidated Statement of Fin

5、ancial PositionInterim Condensed Consolidated Statement of Changes in EquityInterim Condensed Consolidated Statement of Cash Flows Notes to the Interim Condensed Consolidation Financial StatementsDefinitions245265354 55 57 59 62 93Pharmaron Beijing Co.,Ltd.Interim Report 20232Corporate InformationEX

6、ECUTIVE DIRECTORSDr.LOU Boliang(樓柏良)(Chairman)Mr.LOU Xiaoqiang(樓小強)Ms.ZHENG Bei(鄭北)NON-EXECUTIVE DIRECTORSMr.CHEN Pingjin(陳平進)(ceased on Jun 21,2023)Mr.HU Baifeng(胡柏風)Mr.LI Jiaqing(李家慶)Mr.ZHOU Hongbin(周宏斌)(ceased on Jun 21,2023)INDEPENDENT NON-EXECUTIVE DIRECTORSMr.TSANG Kwan Hung Benson(曾坤鴻)Mr.YU J